Table 1.

Ongoing clinical trials for the evaluation of neoadjuvant therapy in locally advanced gallbladder cancer. BTC: biliary tract cancer. GBC: gallbladder cancer. OS: overall survival. ORR: overall response rate. RCT: radiochemotherapy. RT: radiotherapy.

NCT Number	Study Phase	Condition	Study Size	Treatment Agent	Primary End Point	Institution	Completition
NCT03673072	III	Incidental GBC and BTC	300	Gemcitabine + cisplatin perioperative vs. adjuvant	OS	Krankenhaus Nordwest, Germany	November 2024
NCT02867865	II/III	GBC	314	Gemcitabine + cisplatin alone vs. RT + gemcitabine + cisplatin	OS	Tata Memorial Hospital, India	August 2022
NCT04308174	II	BTC	45	Gemcitabine + cisplatin vs. gemcitabine + cisplatin + durvalumab	R0 resection rate	Asan Medical Center, Korea	December 2023
NCT04559139	II/III	GBC	186	Gemcitabine + cisplatin perioperative vs. adjuvant	OS	Emory University, Winship Cancer Institute, United States	September 2023
NCT04480190	I	BTC	12	Gemcitabine + cisplatin followed by RCT (5FU + RT)	Therapy completion	University of Cincinnati Medical Center, United States	February 2029